Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 31st total of 10,160,000 shares. Approximately 19.8% of the company’s shares are sold short. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is presently 13.0 days.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GPCR shares. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Price Performance

GPCR stock opened at $29.97 on Monday. The business has a 50-day moving average price of $29.65 and a 200 day moving average price of $35.20. Structure Therapeutics has a 1-year low of $23.50 and a 1-year high of $62.74. The company has a market capitalization of $1.72 billion, a P/E ratio of -40.50 and a beta of -2.78.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $40,000. Assetmark Inc. boosted its position in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics during the 3rd quarter valued at $202,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.